Quick Facts: Isoniazid Treatment Domains

• Active Tuberculosis: Used as a required component in a multiple-drug regimen to treat active infection by Mycobacterium tuberculosis.
• Latent Tuberculosis Infection: Utilized for preventive therapy to decrease the risk of latent infection progressing to active disease.

---

Isoniazid: Main Uses and Benefits

Isoniazid is an established antibacterial compound that is a foundational agent in the treatment of diseases caused by Mycobacterium tuberculosis. The medication's principal application is in the management of tuberculosis (TB), which primarily impacts the lungs but can affect other bodily sites.

The therapeutic benefits of Isoniazid are categorized into two major areas:

1. Treatment of Active Tuberculosis: For confirmed cases of active TB, Isoniazid is administered as part of a combination regimen. The use of multiple concomitant anti-tuberculosis medications is essential to ensure complete eradication of the infection and to guard against the development of drug resistance.
2. Preventive Therapy: Isoniazid is also a component of treatment plans designed to manage latent tuberculosis infection. This preventive course is intended for individuals who have been infected with the bacteria but do not yet have active disease, with the goal of preventing the future development of active TB. The duration of this preventive therapy can vary, often lasting for several months or longer.

Patients should adhere strictly to the prescribed regimen for the full duration of treatment, which is critical for successful clinical outcomes.

Regulatory References

1. NIH MedlinePlus guidance

Who Can and Cannot Use Isoniazid

Eligibility for Isoniazid (INH) use is strictly defined by regulatory authorities and centers primarily on the patient's liver health and age. The medication is contraindicated in any patient presenting with acute liver disease of any etiology or a documented history of hepatic injury associated with prior Isoniazid use. Patients with a known severe hypersensitivity to the drug must also not use it.

Eligibility and Restriction Summary

Population Status	Eligibility Rule (Official Labeling)
Absolute Contraindication	Acute liver disease; History of Isoniazid-induced hepatic injury; Severe hypersensitivity.
Generally Allowed	Adults, adolescents, and children ge 3 months of age for active and latent tuberculosis indications.
Restricted Use/Caution	Chronic liver disease or renal impairment (especially for slow acetylators); Age ge 35; Diabetes mellitus; Pre-existing seizure disorders or psychosis; Daily alcohol users.

Use in pregnancy is classified by the FDA as Category C and is generally recommended only for active tuberculosis where the maternal benefit outweighs the potential risk. For lactating women, use is not generally contraindicated, but both mother and infant should receive Pyridoxine (Vitamin B6) supplementation.

Official Interactions with Other Medicines and Products

Isoniazid's interaction profile is defined by its effects on the metabolism and pharmacodynamics of other substances, as documented in regulatory sources.

Category	Documented Interaction Patterns
Metabolic Interactions	Isoniazid is documented as an inhibitor of hepatic enzymes, including CYP2C19 and CYP3A4. This pharmacokinetic interaction reduces the clearance and increases the plasma concentrations of co-administered medicines, such as phenytoin, carbamazepine, warfarin, and theophylline.
Additive Toxicity	A pharmacodynamic risk is noted with co-administration of alcohol and other neurotoxic agents, which may lead to an additive risk of severe central nervous system (CNS) effects or hepatotoxicity. Co-administration with disulfiram is formally restricted due to this risk.

Interaction-Related Restrictions and Constraints

Timing Requirement: Regulatory labeling requires that aluminum-containing antacids not be taken within 1 hour of Isoniazid administration, as they significantly reduce its absorption.

Substance Interaction: Due to Isoniazid's minor MAO-inhibiting activity, consumption of tyramine- and histamine-rich foods (e.g., aged cheeses, selected fish) is officially cautioned against, as it may lead to adverse pharmacodynamic reactions.

Population Note: The risk and severity of drug interactions are formally stated to be heightened in slow acetylators and patients with hepatic impairment.

Mandatory Prodrug Activation by Bacterial KatG

Изониазид (INH) is an inert prodrug that must undergo mandatory enzymatic conversion to become active. This activation relies entirely on the bacterial enzyme KatG (catalase-peroxidase) found within Mycobacterium tuberculosis, which oxidizes INH to create the final active molecule: the nicotinoyl-NAD adduct. This step dictates the mechanism's specificity to the bacterium and its onset kinetics.

---

Blockade of Mycolic Acid Synthesis via InhA Inhibition

The active nicotinoyl-NAD adduct acts as a tight-binding competitive inhibitor of the bacterial enzyme InhA, a core component of the pathway responsible for making mycolic acids. By blocking InhA, the drug prevents the completion of the mycobacterial cell wall structure, resulting in the loss of cell integrity and subsequent microbial disruption.

---

️ Bactericidal Action Tied to Metabolic State

The resulting mechanism leads to a rapid bactericidal (cell-killing) effect against actively multiplying M. tuberculosis cells, while only exerting a bacteriostatic (growth-halting) effect on slow-growing or dormant organisms. This functional difference is a mechanistic constraint demonstrating that the mechanism's activity profile is directly tied to the target organism's metabolic rate and the continuous need for cell wall synthesis.

Isoniazid is administered primarily via the oral route, utilizing tablets or solution, though an injectable solution for intravenous (IV) or intramuscular (IM) use is used for short-term situations when oral intake is not feasible. For the oral form, administration typically occurs on an empty stomach, one hour before or two hours after a meal, to prevent potential reduction in absorption. Furthermore, aluminum-containing antacids should be separated from Isoniazid intake by at least one to two hours.

Dosing is determined by body weight and the specific regimen. For the daily treatment of active disease in adults, the dose is typically 5 mg/kg of body weight, not to exceed a maximum of 300 mg per day. Alternatively, higher intermittent doses of 15 mg/kg (up to 900 mg) are used two or three times weekly in specific supervised protocols. Pediatric patients receive a higher weight-based dose, usually 10-15 mg/kg daily, also capped at 300 mg.

The total duration of Isoniazid usage is always long-term, spanning multiple months. It is utilized across both an initial phase and a longer continuation phase for active disease, or maintained daily for six to nine months for preventive therapy. If a daily dose is missed, it is standard practice to resume the regular schedule without taking a double dose to catch up.

Isoniazid: Recent Clinical Evidence

Clinical research continues to evaluate and refine the role of Isoniazid (INH), particularly in the context of shorter treatment regimens and drug-resistant strains of Mycobacterium tuberculosis.

---

Latent Tuberculosis Infection (LTBI) Treatment

For the treatment of LTBI, clinical guidelines increasingly favor short-course, rifamycin-based regimens (e.g., Isoniazid and Rifapentine weekly for three months) over the traditional 6- or 9-month daily isoniazid monotherapy. This preference is driven by evidence showing that the shorter regimens maintain comparable efficacy while demonstrating a higher rate of treatment completion and generally lower toxicity.

However, 6- and 9-month isoniazid monotherapy regimens (6H/9H) remain effective and are important alternative options when short-course rifamycin-based regimens are contraindicated, such as due to potential drug interactions (e.g., with certain antiretroviral therapies for HIV/AIDS) or patient intolerance to rifamycins.

---

Drug-Resistant Tuberculosis (DR-TB)

Isoniazid remains a crucial component of first-line therapy for drug-susceptible active tuberculosis. For treatment of strains resistant only to isoniazid (Isoniazid monoresistance), clinical outcomes are generally excellent when treated with a four-drug regimen including rifampin, pyrazinamide, and ethambutol, often with the addition of a fluoroquinolone. However, newer, shorter regimens for this form of resistance are being sought.

Research on the use of high-dose Isoniazid in treating multidrug-resistant tuberculosis (MDR-TB) continues, with some studies suggesting that high doses (10–15 mg/kg daily) may retain activity against strains with certain mutations (e.g., inhA mutations) that confer low-level isoniazid resistance. Conversely, high-dose Isoniazid has shown negligible activity against strains with high-level resistance caused by katG mutations. This highlights the ongoing effort to personalize DR-TB treatment based on the specific resistance-conferring mutation.

Common questions about Изониазид (FAQ)

Q: Does Isoniazid have to be taken with food, or should I take it on an empty stomach?

Official regulatory instructions advise that Isoniazid should typically be taken on an empty stomach. Regulatory instructions typically recommend separation from meals, such as one hour before or two hours after eating. This timing separation is recommended because taking the medicine on an empty stomach is intended to prevent a potential reduction in the absorption of the drug.

Q: What is the correct dose of Isoniazid for an adult?

According to official drug labeling, the dose of Isoniazid is determined by body weight and the specific treatment regimen being used. For active tuberculosis treated daily, the dose is calculated based on body weight. The dose is generally capped at 300 mg per day for a daily regimen, though alternative higher intermittent doses are utilized in specific, supervised protocols.

Q: Does Isoniazid interact with common blood thinners like Warfarin?

Regulatory documents state that Isoniazid can interact with medicines like Warfarin. Isoniazid is documented to inhibit certain liver enzymes, which can increase the concentration of Warfarin in the blood. Official guidance notes that the plasma concentration of Warfarin may need monitoring when these medicines are used together.

Q: Why are antacids not allowed to be taken close to the time of Isoniazid administration?

Official warnings require that antacids containing aluminum be separated from Isoniazid administration by one to two hours. This separation is necessary because these antacids can significantly interfere with and reduce the amount of Isoniazid the body is able to absorb. Observing the required timing helps manage the potential reduction in effectiveness caused by the absorption issue.

Q: Who should not take Isoniazid?

Regulatory authorities have established that Isoniazid is contraindicated in patients with a history of severe hypersensitivity (allergic reaction) to the drug. It is also restricted for use in individuals who have acute liver disease or a history of liver injury that was associated with previous Isoniazid use.

Q: How should I dispose of unused Isoniazid pills?

To properly dispose of unused or expired Isoniazid, official guidelines recommend using an authorized drug take-back program if one is available. If a program is not available, the medication can be mixed with an undesirable substance like dirt or used coffee grounds and placed into a sealable container before being thrown in the household trash. It is important that personal information on the original label is removed or obscured.

Q: Do I need to take a vitamin supplement while on Isoniazid?

Some health authorities recommend Pyridoxine (Vitamin B6) supplementation for patients taking Isoniazid. This is often suggested to help reduce the risk of peripheral neuropathy, which is a known neurological adverse effect of the medicine. All decisions regarding supplements should be discussed with the prescribing healthcare professional.

Storage and Disposal Requirements

Isoniazid must be stored at Controlled Room Temperature, defined as 68 F to 77 F (20 C to 25 C). The medication requires protection from both moisture and direct light. It is essential to Keep from Freezing.

The medication must be stored in a Tightly Closed Container and placed Out of the Reach of Children to prevent accidental ingestion.

Disposal Guidelines

Unused or expired Isoniazid should be discarded using an authorized drug take-back program. If a program is unavailable, household disposal requires mixing the drug with an undesirable substance (such as dirt) and placing it in a sealable container before throwing it in the trash. The original container's label must have all personal information scratched out prior to disposal.